Pharmaceutical Pollution in India: Industrial Clustering, Environmental Hotspots, Antimicrobial Resistance, and Regulatory Gaps.

PURPOSE OF REVIEW: Pharmaceutical pollution has emerged as a critical threat to environmental integrity and public health globally, with India occupying a uniquely prominent position as both the world's leading generic drug manufacturer and a major hotspot of active pharmaceutical ingredient (API) contamination. This review synthesizes current evidence on the distribution, magnitude, and health consequences of pharmaceutical pollution across India's principal manufacturing clusters and river systems, with particular emphasis on antimicrobial resistance (AMR) as a downstream public health consequence.

RECENT FINDINGS: Evidence environmental monitoring data, regulatory documentation, and case studies from Patancheru-Hyderabad (Telangana) and Baddi-Barotiwala-Nalagarh (Himachal Pradesh), we highlight evidence demonstrating that active pharmaceutical ingredients (APIs) in pharmaceutical manufacturing hotspots frequently occur at concentrations far exceeding recommended environmental thresholds, while also documenting the occurrence of hazardous heavy metals and organic solvents in affected environments. We further assess the regulatory landscape, including the Environment (Protection) Act (1986), Biomedical Waste Management Rules (2016), Zero Liquid Discharge mandates, and recent CPCB draft guidelines (2025), and identify persistent structural gaps in monitoring, enforcement, and compound-specific discharge standards. The review concludes with evidence-based recommendations for strengthening surveillance frameworks, integrating ecological risk quotient approaches, and aligning Indian policy with emerging international standards. Addressing pharmaceutical pollution is not merely an environmental imperative but an essential component of the global effort to contain AMR, protect vulnerable populations, and achieve health sustainability in low- and middle-income countries.